InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.210 0.005 (2.33%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$126 DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved 15 Dec 2022 8:55AM $0.150 $0.210 risen by 40%
$126 CLARITY 2.0 COVID-19 Study Outcome 13 Dec 2022 8:46AM $0.165 $0.210 risen by 27.27%
$126 Constitution 29 Nov 2022 3:19PM $0.165 $0.210 risen by 27.27%
$126 Results of Meeting 29 Nov 2022 3:16PM $0.165 $0.210 risen by 27.27%
$126 Chair address and CEO presentation to AGM 29 Nov 2022 9:16AM $0.160 $0.210 risen by 31.25%
$126 Investor Briefing 23 Nov 2022 8:36AM $0.150 $0.210 risen by 40%
$126 Letter to Shareholders, Notice of AGM & Proxy Form 27 Oct 2022 12:25PM $0.160 $0.210 risen by 31.25%
$126 AusBioInvest Presentation, including FSGS recruitment update 27 Oct 2022 8:48AM $0.175 $0.210 risen by 20%
$126 Quarterly Appendix 4C and Activities Report 27 Oct 2022 8:38AM $0.175 $0.210 risen by 20%
$126 Dimerix Receives A$6.0M R&D Tax Incentive Rebate 25 Oct 2022 9:03AM $0.175 $0.210 risen by 20%
$126 Notification of Date of 2022 AGM 4 Oct 2022 8:49AM $0.145 $0.210 risen by 44.83%
$126 Investor Presentation 15 Sep 2022 9:02AM $0.140 $0.210 risen by 50%
$126 Appendix 4G and Corporate Governance Statement 29 Aug 2022 8:51AM $0.160 $0.210 risen by 31.25%
$126 Appendix 4E and 2022 Annual Report 29 Aug 2022 8:46AM $0.160 $0.210 risen by 31.25%
$126 CLARITY 2.0 COVID-19 Study Concludes Recruitment 18 Aug 2022 8:38AM $0.150 $0.210 risen by 40%
$126 Notification of cessation of securities - DXB 10 Aug 2022 2:43PM $0.170 $0.210 risen by 23.53%
$126 New Patent Family Application for DMX-700 9 Aug 2022 8:48AM $0.160 $0.210 risen by 31.25%
$126 Quarterly Appendix 4C and Activities Report 27 Jul 2022 8:38AM $0.150 $0.210 risen by 40%
$126 Notification regarding unquoted securities - DXB 25 Jul 2022 3:00PM $0.145 $0.210 risen by 44.83%
$126 DMX-700 Study Shows Significant 80% Reduction in Lung Injury 4 Jul 2022 8:40AM $0.125 $0.210 risen by 68%
$126 REMAP-CAP COVID-19 Study Analysis Update 27 Jun 2022 8:36AM $0.125 $0.210 risen by 68%
$126 New Clinical Trial for DMX-200 in Diabetic Kidney Disease 7 Jun 2022 8:59AM $0.160 $0.210 risen by 31.25%
$126 Dimerix to Present at BIO International Convention 6 Jun 2022 8:59AM $0.170 $0.210 risen by 23.53%
$126 Phase 3 FSGS Kidney Trial First Patient Recruited 31 May 2022 9:07AM $0.145 $0.210 risen by 44.83%
$126 Release of Shares from Voluntary Escrow 18 May 2022 8:59AM $0.145 $0.210 risen by 44.83%

351 - 375 of 745 results

Page 15 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.